Showing 8961-8970 of 10817 results for "".
- US FDA Issues Draft Updated Recommendations on Submitting a New 510(k) for Device Modificationshttps://practicaldermatology.com/news/us-fda-issues-draft-of-updated-recommendations-on-submitting-a-new-510k-for-device-modifications/2458471/The U.S. Food and Drug Administration (FDA) issued draft updated recommendations to help manufacturers determine when they are required to notify the FDA about modifications made
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- It's Official: Botox Makes Us Feel Better About Ourselveshttps://practicaldermatology.com/news/its-official-botox-makes-us-feel-better-about-ourselves/2458516/Patient satisfaction with overall facial appearance increases by 28 percent with botulinum toxin type A injections to the glabellar rhytids, according to new research in the Aesthetic Surgery Journal. In the study, sati
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Dr. Ann Marshak-Rothstein Takes Home 2016 Lupus Insight Prize for Cutaneous Lupus Researchhttps://practicaldermatology.com/news/dr-ann-marshak-rothstein-takes-home-2016-lupus-insight-prize-for-cutaneous-lupus-research/2458520/Ann Marshak-Rothstein, PhD, a professor of Medicine/Rheumatology at the University of Massachusetts Medical received the 2016 Lupus Insight Prize for her research on cutaneous lupus. The award was announced at FOCIS 2016, the 16th Annual M
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,
- Meet Alastin's Restore & Renew Anti-Aging Linehttps://practicaldermatology.com/news/meet-alastins-restore-renew-anti-aging-line/2458570/ALASTINTM Skincare, Inc., is rolling the newest addition to their portfolio -- the Restore & Renew Anti-Aging line. The line consists of four products: the Restorative Skin ComplexTM, the Restorative Eye Tre
- Galderma Gives Chefs a Hand with New Excipial Partnershiphttps://practicaldermatology.com/news/galderma-gives-chefs-a-hand-with-new-excipial-partnership/2458582/Galderma Laboratories, L.P., maker of Excipial, is teaming up with the American Culinary Federation to help chefs treat their dry hands. Professional chefs spend about 14 hours a day in the kitchen, prepping food and washing their hands,
- Personalized Medicine In Action: New Biomarker May Pinpoint Aggressive BCChttps://practicaldermatology.com/news/personalized-medicine-in-action-new-biomarker-may-pinpoint-aggressive-bcc/2458598/A biomarker associated with basal cell carcinoma around the eye may help signal which tumors are likely to be aggressive, report researchers from University of Michigan (U-M) at Ann Arbor. The findings, which appear in JAMA Oncology, may help eliminat